Honest, direct answers for investors, engineers, healthcare professionals, and potential partners exploring BIQADX.
About stage & products
No. BIQADX products are in research, concept, prototype, and engineering development stages. Nothing is commercially available. Our calls-to-action say ‘Partner With BIQADX’ — not ‘Buy Now’ — because that is an accurate description of what we are offering.
Not yet. Clinical validation is a future milestone for programs that have completed sufficient engineering development to enter validation studies. We will communicate this clearly and publicly when it occurs.
Primarily a research company at this stage, building the technology foundation for future products. We have patent applications, engineering blueprints, and prototype development underway — but no commercially ready products.
Recognition under the Department for Promotion of Industry and Internal Trade’s Startup India program, certifying BIQADX as a qualifying Indian startup for associated government scheme benefits. It is not a product certification or quality endorsement.
About investment & partnership
Seed to pre-Series A. We are approaching government innovation grants (SISFS, BIRAC, DST), angel networks, and deep-tech incubators. We are transparent about our current stage and development timeline.
Co-development rights, IP access under appropriate frameworks, first-mover positioning in a large underserved market, and the opportunity to build something that matters. We are not offering licensing fees or commercial terms — we are offering genuine co-building partnerships.
About sustainability
No. Eco-Labware is an R&D program researching biodegradable alternatives to medical single-use plastics. Products are in concept, research, and early prototype stage. The program is anchored by patent application No. 202531060831, filed and under examination.
IP, funding & pilots
Not yet. We have multiple patent applications filed at the Indian Patent Office, including lead application No. 202531060831 for biodegradable medical consumables, which is currently under examination. We state our IP status accurately because investors and partners deserve precision on this point.
We do not provide target dates for commercial availability because doing so before analytical verification and regulatory submissions would be speculative. We are building toward first-generation analytical verification milestones and will share timelines when they are grounded in evidence.
We are currently funded by the founders and are actively engaging with investors, government grant programs including SISFS/KIIF and BIRAC, and strategic partners. We welcome conversations with mission-aligned investors.
Most point-of-care testing companies adapt conventional reagent-dependent testing for smaller form factors. We are attempting something more fundamental: diagnostic platforms that reduce or eliminate reagent dependency using physical measurement and computational intelligence. This is harder, slower, and riskier — but if it works, it changes the economics and accessibility of every test built on the platform.
We are at a pre-clinical, prototype stage and do not currently offer pilot deployments. We welcome partnership conversations that could lead to future pilot engagements as the technology matures.